Cefditoren in the respiratory tract infections of the community;Cefditoren en las infecciones de vías respiratorias bajas adquiridas en la comunidad

Revista Espanola de Quimioterapia

Volumn 22, Issue 3, 2009, Pages 144-150

  Barberan J ^a   Mensa, J ^b  

^a HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cefditoren; Haemophilus influenzae; Respiratory tract infections; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFACLOR; CEFDITOREN; CEFUROXIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERYTHROMYCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

BACTERIAL STRAIN; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG TOLERABILITY; HAEMOPHILUS INFLUENZAE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA PNEUMONIAE; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; COMMUNICABLE DISEASE; DRUG EFFECT; HAEMOPHILUS INFECTION; MICROBIOLOGY; PNEUMOCOCCAL INFECTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 74249107504     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Huovinen P, Cars O. Control of antimicrobial resistance: time for action. The essentials of control are already well known. BMJ 1998;317:613-14.
2. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 1995;273:214-9.
3. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice Guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
4. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
5. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease: a prospective study of 200 patients. N Engl J Med 1969;280:397-404.
6. Ballester F, Pérez-Hoyos S, Rivera ML, Merelles T, Tenías JM, Soriano JB et al. Patrones de frecuentación y factores asociados al ingreso en el hospital de las urgencias hospitalarias por asma y enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 1999;35:20-6.
7. Aspa J, Rajas O, de Castro FR. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother 2008;9:229-41.
8. García-Rodríguez JA, Muñoz JL. Etiología de la infección respiratoria. Med Clin Monogr (Barc) 2004;5:2-5.
9. Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect 2006;12 (Suppl. 3):12-24.
10. Bouza E, Rodríguez-Creisems M. ¿Son las quinolonas los fármacos de elección en la neumonía causada por microorganiosmos del género Legionella? Enferm Infect Dis Microbiol Clin 1999;17 (Supl. 1):19-23.
11. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108 (Supl. 2):43-52.
12. Sethi S. Infectious Etiology of Acute Exacerbations of Chronic Bronchitis. Chest 2000;117:S380-5.
13. Pérez-Trallero E, García de la Fuente C, García Rey C, Baquero F, Aguilar L, Dal Ré R et al. Geographical and Ecological Analysis of Resistance, Coresistance, and Coupled Resistance to Antimicrobials in Respiratory Pathogenic Bacteria in Spain. Antimicrob Agents Chemother 2005; 49:1965-72.
14. Marco F, Garcia de Lomas J, Garcia-Rey C, Bouza E, Aguilar L, Fernández Mazarrasa C et al. Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999. Antimicrob Agents Chemother 2001;45:3226-28.
15. Aracil B, Gómez Garcés JL, Alós JI y Grupo de Estudio de Infeccion en Atención Primaria de la SEIMC. Enferm Infecc Microbiol Clin 2003;211:31-6.
16. Cantón R, Morosini MI, Loza E, Gómez G, de la Pedrosa E. Infecciones comunitarias. Patrones de sensibilidad a los antimicrobianos utilizados por vía oral de los microorganismos más comunes. Rev Clin Esp 2008;208 (Supl. 3):3-11.
17. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003;7 (Supl. 1):S13-20.
18. Soriano F. Importancia de los parámetros farmacocinéticos y farmacodinámicos en la elección del tratamiento antimicrobiano de la infección respiratoria. Med Clin Monogr (Barc) 2004;5:6-11.
19. Giménez MJ, Gómez-Lus ML, Valdés L, Aguilar L. Situación de la cefalosporina oral de tercera generacion cefditoreno pivoxil en el tratamiento de la infección comunitaria del adulto. Rev Esp Quimioterap 2005;18:210-18.
20. Wellington K, Curran MP. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs 2004;64:2597-618.
21. Tratamiento antibiótico empírico inicial de la neumonia adquirida en la comunidad el paciente adulto inmunocompetente. Rev Esp Quimioter 2003;16:457-66.
22. Tercer documento de consenso sobre el uso de antimicrobianos en la agudización de la enfermedad pulmonar obstructiva crónica. Rev Esp Quimioter 2007;20:93-105.
23. Barberán J, Giménez MJ, Aguilar L, Prieto J. Evidencia cientifica y concepcion global del tratamiento empírico de la infección de vías respiratorias bajas en la comunidad. Rev Esp Quimioter 2004;17:317-24.
24. Karlowsky JA, Critchley IA, Draghi DC, Jones ME, Thornsberry C, Sahm DF. Activity of cefditoren against beta-lactamasepositive and negative Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis 2002;42:53-8.
25. Lerma M, Cebrián L, Giménez MJ, Coronel P, Gimeno M, Aguilar L et al. B-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes. Rev Esp Quimioter 2008;21:149-52.
26. Mattie H. Kinetics of antimicrobial action. Rev Infect Dis. 1981;3:19-27.
27. Soriano F, Granizo JJ, Fenoll A, Gracia M, Fernandez-Roblas R, Esteban J et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four southern European countries (ARISE project) from adult patients: results from the cefditoren surveillance program. J Chemother 2003;15:107-12.
28. Pérez-Trallero E, Marimón JM, Ercibengoa M, Giménez MJ, Coronel P, Aguilar L. Antimicrobial susceptibilities of amoxycillin- nonsusceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect 2007;13:937-40.
29. Fenoll A, Aguilar L, Robledo O, Gimenez MJ, Tarragó D, Granizo JJ et al. Influence of the β-lactam resistance phenotype on the cefuroxime versus cefditoren susceptibility of Streptococcus pneumoniae and Haemophilus influenzae recovered from children with acute otitis media. Journal of Antimicrobial Chemotherapy 2007;60:323-7.
30. Fenoll A, Giménez MJ, Robledo O, Aguilar L, Tarragó D, Granizo JJ et al. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin. J Chemother 2008;20:175-9.
31. Yamada M, Watanabe T, Miyara T, Baba N, Saito J, Takeuchi Y et al. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother 2007;51:3902-7.
32. Soriano F, Granizo JJ, Coronel P, Gimeno M, Rodenas E, Gracia M et al. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents 2004;23:296-9.
33. Li JT, Hou F, Lu H, Li TY, Li H. Phase I clinical trial of cefditoren pivoxil (ME 1207): Pharmacokinetics in healthy volunteers. Drugs Exp Clin Res 1997;23:145-50. (Pubitemid 28458597)
34. Eiros Bouza JM, Valdés Verelst L, Bachiller Luque MR. Contribucion de la farmacodinamia en la elección antimicrobiano para las exacerbaciones de la EPOC. Rev Esp Quimioter 2006;19:220-30.
35. Sádaba B, Azanza JR, Quetglas EG, Campanero MA, Honorato J, Coronel P, Gimeno M. Pharmacokinetic/pharmacodynamic serum and urine profile of cefditoren following single-dose and multiple twice- and thrice-daily regimens in healthy volunteers: a phase I study. Rev Esp Quimioter 2007;20:51-60.
36. Ball P, Baquero F, Cars O, File T, Garau J, Klugman K et al. Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002;49:31-40.
37. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001;47:129-40.
38. Clark CL, Nagai K, Dewasse BE, Pankuch GA, Ednie LM, Jacobs MR et al. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002;50:33-41.
39. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001;14:336-63.
40. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005;127:2231-6.
41. Wilkinson TM, Patel IS, Wilks M, Donalson GC, Weidzcha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1090-5.
42. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Resp J 2002;20 (Supl. 36): 9-19.
43. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
44. Alvarez-Sala JL, Kardos P, Martinez-Beltran J, Coronel P, Aguilar L and the Cefditoren AECB Working Group. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother 2006;50:1762-7.
45. van Zyl L, le Roux JG, LaFata JA, Volk RS, Palo WA, Flamm R et al. Cefditoren pivoxil versus cefpodoxime proxetil for community acquired pneumonia: Results of a multicenter, prospective, randomized, double-blind study. Clin Ther 2002;24:1840-53.
46. Fogarty CM, Cyganowski M, Palo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: A multicenter, prospective, randomized, investigator-blinded, parallelgroup study. Clin Ther 2002;24:1854-70.
47. Ramirez JA, Tucker RM, Bettis RB. Treating acute exacerbations of chronic bronchitis. J Res Dis 2001;22(Supl. 8):75-80.
48. Henry DC, Poling TL, Bettis RB. A double-blind, randomized study of cefditoren vs cefuroxime for AECB. J Respir Dis 2001;22(Supl. 8):69-74.
49. Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L. The Efficacy of Cefditoren Pivoxil in the Treatment of Lower Respiratory Tract Infections, with a Focus on the Per-Pathogen Bacteriologic Response in Infections Caused by Streptococcus pneumoniae and Haemophilus influenzae: A Pooled Analysis of Seven Clinical Trials. Clin Ther 2006;28:2061-9.
50. Granizo J, Aguilar L, Giménez M, Coronel P, Gimeno M, Prieto J. Safety profile of cefditoren: A pooled analysis of data from clinical trials in community-acquired respiratory tract infections. Rev Esp Quimioter 2009;22:57-61.
51. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS et al. Time to Clinical Stability in Patients Hospitalized With Community-Acquired Pneumonia. Implications for Practice Guidelines. JAMA 1998;279:1452-7.
52. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JA. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-71.
53. Reyes Calzada S, Martínez Tomás R, Menéndez Villanueva R. Pacientes Hospitalizados con infección del tracto respiratorio inferior: ventajas del tratamiento secuencial. Med Clin Monogr (Barc) 2006;7:30-5.
54. Guidelines for the Management of Adults with Community-acquired Pneumonia Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention. Am J Respir Crit Care Med 2001;163:1730-54.
55. Carratalá J, Navas E, San Juan R, Soliano F, Rodríguez V. Guía de Recomendaciones en la Terapia Secuencial Antibiótica (TSA). En: Aguado JM, Fortún J. Guías Clínicas SEIMC 2006. www.seimc.org.
56. Sevinç F, Prins JM, Koopmans RP, Langendijk PN, Dankert J, Speelman P. Early switch from intravenous to oral antibiotics: Guidelines and implementation in a teaching hospital. J Antimicrob Chemother 1999;43:601-6.
57. Odenholt I, Cars O. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 2006;58:960-5.
58. Candel González FJ. ¿Cuál es el tratamiento más adecuado como continuación de las cefalosporinas parenterales? Emergencias 2006;18:207-14.